Key Takeaways
- Germany's legal cannabis market is projected to reach $2.92 billion in 2026, cementing its status as the largest regulated market in Europe following the landmark 2024 Cannabis Act (CanG).
- Medical cannabis imports surged to over 218 tonnes annually by mid-2026, a nearly threefold increase compared to pre-reform levels, driven by the reclassification of cannabis as a non-narcotic.
- Price compression has hit the retail level, with pharmacy flower prices falling approximately 46% to €4.52 per gram, significantly undercutting traditional black-market rates.
- Telemedicine and online prescriptions have become the primary growth engine, with patient prescription volumes increasing by 3,300% since the 2024 regulatory shift.
- Canada remains the dominant supplier, accounting for nearly 50% of all medical cannabis imports, though domestic production from firms like Demecan is scaling to meet rising demand.
Germany has officially emerged as the undisputed leader of the European cannabis industry, with its regulated market entering a phase of rapid structural expansion. Following the implementation of the Cannabis Act (CanG) in April 2024, which decriminalized possession and reclassified medical cannabis, the nation has seen an unprecedented boom in both patient access and commercial activity. The market is currently valued at approximately $2.92 billion for 2026, with forecasts suggesting it could reach $13.95 billion by 2035.
The medical sector remains the primary commercial driver, as nationwide recreational retail shops have yet to be established under the current "Pillar 1" legislation. Instead, the market has transitioned toward a highly liberalized pharmaceutical model where medical cannabis is dispensed through a network of over 20,000 pharmacies. This shift has been facilitated by the removal of cannabis from the Narcotics Act (BtMG), allowing doctors to prescribe it as a standard "red prescription" medicine.
International operators are aggressively positioning themselves to capture share in this maturing landscape. High Tide (HITI) has expanded its footprint through its subsidiary Remexian Pharma, while Canadian giants such as Tilray Brands (TLRY) and Aurora Cannabis (ACB) continue to leverage their EU-GMP certified facilities to dominate the supply chain. Curaleaf (CURA) has also made significant inroads, recently launching a $272 million hostile bid for Aurora to consolidate its European influence.
Despite the growth, the market faces significant regulatory and economic headwinds. Price compression is a major concern for cultivators, as the influx of low-cost, high-THC products from international markets has driven prices down by more than 30% in the last year. Furthermore, German lawmakers are currently debating stricter rules for telemedicine, which could require in-person doctor visits and potentially slow the current rate of patient acquisition.
The success of the German model is serving as a blueprint for continental reform, with neighboring countries like Poland, the UK, and France closely monitoring the impact on public health and crime. While the "Pillar 2" commercial pilot programs in cities like Berlin and Munich are still under development, the current medical-led framework has already established Germany as the global destination for cannabis investment and export.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.